API Synthesis and Manufacturing, Large Molecule

The collaboration partner for Willow is focused on more sustainable methods to manufacture intermediates and APIs at reduced cost and less waste, in addition to looking for Willow’s expertise in developing and scaling key ingredients.

Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.

The new excipients manufacturing facility is expected to be completed in 2025.

When one is using continuous hot-melt extrusion to enhance solubility, process control is essential.

Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.

This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility.

Epinephrine is a critical medication used during life-threatening conditions that can affect any age and any person.

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

Roquette’s acquisition of Crest Cellulose is designed to reinforce its presence in India and other countries in Asia.

Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.

ImmunoGen and Eli Lilly and Company have entered into an agreement that gives Lilly exclusive rights to research, develop, and commercialize ADCs designed for targets selected by Lilly from ImmunoGen’s camptothecin technology.

In a pandemic, genetic vaccines offer several advantages over traditional approaches.

Homology Medicines discusses how the clinical-stage biopharmaceutical company met its need for supply of adeno-associated virus vectors.

Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.

CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2.

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.

The new GMP conditioning product offering is designed to support clinical phase and commercialization stages of cell and gene therapy production.

Innovation in manufacturing technologies must occur to ensure the availability of gene and cell therapies.

New platform technologies, advanced modeling tools, and addressing patient needs are important developments.

ADC Biotechnology will invest downstream formulation, fill/finish capabilities, and Lock-Release conjugation technology.

FDA grants support US research in continuous manufacturing monitoring and control techniques for bio/pharmaceutical manufacturing at Rutgers, MIT, and Georgia Tech.

Avalon and Weill will co-develop bio-production and standardization procedures for CAR-T therapy.

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

The changing regulatory and manufacturing environment is ushering in a new approach to drug development.

The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.

CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.

Report predicts PAT, NIRS, continuous bioprocessing, and a ‘technological arms race’ could improve biopharma manufacturing efficiencies.